Rocco Pastano

Milan, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

Repeated courses of sequential venetoclax and donor lymphocyte infusions in a patient with relapsed high-risk myelodysplasia following allogeneic stem cell transplantation: a case report.

Repeated courses of sequential venetoclax and donor lymphocyte infusions in a patient with relapsed high-risk myelodysplasia following allogeneic stem cell transplantation: a case report.

Journal: Frontiers in immunology

Published: March 26, 2026

Haploidentical allogeneic hematopoietic stem cell transplantation in relapsed/refractory Hodgkin lymphoma in the era of novel agents: a single-center experience.

Haploidentical allogeneic hematopoietic stem cell transplantation in relapsed/refractory Hodgkin lymphoma in the era of novel agents: a single-center experience.

Journal: Leukemia & lymphoma

Published: March 05, 2026

Trends in GVHD Epidemiology, Prophylaxis and Management: The Gruppo Italiano per il Trapianto di Midollo Osseo, Cellule Staminali Emopoietiche e Terapia Cellulare (GITMO) GVHD24 Study.

Trends in GVHD Epidemiology, Prophylaxis and Management: The Gruppo Italiano per il Trapianto di Midollo Osseo, Cellule Staminali Emopoietiche e Terapia Cellulare (GITMO) GVHD24 Study.

Journal: American journal of hematology

Published: August 22, 2025

Daratumumab plus bortezomib and dexamethasone as a bridge to allogeneic transplantation in refractory T-cell lymphoblastic lymphoma.

Daratumumab plus bortezomib and dexamethasone as a bridge to allogeneic transplantation in refractory T-cell lymphoblastic lymphoma.

Journal: Annals of hematology

Published: May 14, 2025

Long-Term Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma: An Italian Multicenter Collaborative Study.

Long-Term Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma: An Italian Multicenter Collaborative Study.

Journal: Transplantation and cellular therapy

Published: February 01, 2025

Venetoclax Plus Intensified Chemoimmunotherapy as a Bridge to Allogeneic Stem Cell Transplantation in Richter Syndrome: Report of Two Cases.

Venetoclax Plus Intensified Chemoimmunotherapy as a Bridge to Allogeneic Stem Cell Transplantation in Richter Syndrome: Report of Two Cases.

Journal: Hematology reports

Published: July 28, 2024

Peripheral blood stem cell versus bone marrow graft for patients ≥60 years undergoing reduced intensity conditioning haploidentical transplantation for acute myeloid leukemia in complete remission: An analysis of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

Peripheral blood stem cell versus bone marrow graft for patients ≥60 years undergoing reduced intensity conditioning haploidentical transplantation for acute myeloid leukemia in complete remission: An analysis of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

Journal: American journal of hematology

Published: November 27, 2023

Non-hepatosplenic extramedullary manifestations in patients affected by Chronic myelomonocytic leukemia. Case report and meta-analysis of the published series.

Non-hepatosplenic extramedullary manifestations in patients affected by Chronic myelomonocytic leukemia. Case report and meta-analysis of the published series.

Journal: Leukemia & lymphoma

Published: July 14, 2023

Hematological disorders after salvage PARPi treatment for ovarian cancer: Cytogenetic and molecular defects and clinical outcomes.

Hematological disorders after salvage PARPi treatment for ovarian cancer: Cytogenetic and molecular defects and clinical outcomes.

Journal: International journal of cancer

Published: March 11, 2022

Outcome of allogeneic transplantation for mature T-cell lymphomas: impact of donor source and disease characteristics.

Outcome of allogeneic transplantation for mature T-cell lymphomas: impact of donor source and disease characteristics.

Journal: Blood advances

Published: August 06, 2021

Pre-existing immune checkpoints activation predicts relapse after allogeneic stem cell transplantation in lymphoma.

Pre-existing immune checkpoints activation predicts relapse after allogeneic stem cell transplantation in lymphoma.

Journal: Bone marrow transplantation

Published: November 01, 2020

Efficacy of venetoclax based salvage chemotherapy followed by "Minimal Residual Disease driven"-venetoclax maintenance therapy post-allotransplant in a young patient with high risk primary refractory acute myeloid leukemia.

Efficacy of venetoclax based salvage chemotherapy followed by "Minimal Residual Disease driven"-venetoclax maintenance therapy post-allotransplant in a young patient with high risk primary refractory acute myeloid leukemia.

Journal: Leukemia & lymphoma

Published: May 05, 2020

Showing 1-12 of 18

Last Updated: 09/26/2026